Top Markets
Coin of the day
Liminatus Pharma, Inc. Class A Common Stock Liminatus Pharma, Inc. Class A Common Stock

Liminatus Pharma, Inc. Class A Common Stock

LIMN
Rank in Stocks #32695
Liminatus Pharma, Inc. is an immuno-oncology firm, currently in its clinical... Liminatus Pharma, Inc. is an immuno-oncology firm, currently in its clinical development phase, dedicated to pioneering new treatments for cancer. The company's headquarters are located in La Palma, California.
Share Price
$0.1407
Market Cap
$9.45M
Change (1 day)
0.50%
Change (1 year)
-96.48%
Country
US
Trade Liminatus Pharma, Inc. Class A Common Stock (LIMN)

Category

P/E ratio for Liminatus Pharma, Inc. Class A Common Stock (LIMN)
P/E ratio as of 2026 TTM: 0
According to Liminatus Pharma, Inc. Class A Common Stock latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Liminatus Pharma, Inc. Class A Common Stock from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
29.20 -
US
30.62 -
NL
- -
CH
- -
KR
18.38 -
BE
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.